enGene Therapeutics Inc.(ENGN)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
enGene Therapeutics Inc. (ENGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ENGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), enGene Therapeutics Inc. reports net income of $-32.5M, free cash flow of $-18.9M. Top institutional holders of ENGN by reported 13-F value include FCPM III SERVICES B.V., BML Capital Management, Siren, L.L.C., based on the most recent SEC filings. ENGN trades on the Nasdaq exchange and files with the SEC under CIK 1980845. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for enGene Therapeutics Inc. directly from SEC EDGAR.
Net Income
$-32.5M
Free Cash Flow
$-18.9M
Institutions holding ENGN
Institutional investors reporting a position in enGene Therapeutics Inc. on SEC Form 13F.
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Price Chart
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
AI-extracted from the 10-Q filed 2026-09-08 — Q3 FY2026 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Clinical-stage biotech enGene reported $20.1M R&D and $13.9M G&A expenses for Q3 2026, reducing workforce by 50% to preserve $266.3M in cash and plan Q4 2026 BLA submission for detalimogene.
Biggest Revenue Drivers
Largest Expense Items
Research and development$20.1M-11% QoQ
Lower manufacturing costs for detalimogene; offset by restructuring-related personnel severance and accelerated vesting.
General and administrative$13.9M+89% QoQ
Higher personnel costs ($10.8M) driven by June 2026 workforce reduction severance and stock-based compensation acceleration.
Interest expense$0.8M+11% QoQ
Interest on $25.0M term loan drawn January 2026 under Second Amended Loan Agreement with Hercules.
Margins: Company is pre-revenue with gross margins not applicable. Operating loss of $34.0M for Q3 reflects ongoing R&D and restructuring charges, partially offset by $2.4M interest income on $266.3M in cash and marketable securities.
Watch Items from the Filing
50% workforce reduction announced June 2026; company estimates $5.6–$6.1M restructuring costs plus $5.0–$5.5M stock-based compensation expense through Q4 2026.
Accumulated deficit of $464.5M as of July 31, 2026; company is pre-revenue and expects cash sufficient for 12+ months but will need additional funding for continued development.
Detalimogene pivotal Phase 2 cohort showed 54% any-time complete response rate but only 13.3% at 12 months; FDA meeting and BLA submission targeted Q4 2026.
New cohort testing detalimogene with surfactant rinse (polidocanol) added to LEGEND trial; company suspended enrollment in other cohorts to preserve cash pending FDA feedback.
Chief Medical Officer Hussein Sweiti resigned June 2026; interim CMO appointed. Company incurred $0.7M severance and $1.2M accelerated stock vesting for this departure.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
